PRCT vs NTRA vs ISRG vs EXAS vs HOLX

For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.

2% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate PROCEPT BioRobotics Corporation (PRCT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -39. 3% for PROCEPT BioRobotics Corporation (PRCT). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus PRCT's -39. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 943% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.

2% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -31. 0% for PROCEPT BioRobotics Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -33. 7% for PRCT. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 582. 8x for Exact Sciences Corporation — 565. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRCT: 74. 9% to $44. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, PRCT: -39. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRCT is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; ISRG is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.